Trials / Completed
CompletedNCT04867785
A Study of LY3437943 in Participants With Type 2 Diabetes
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 281 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 43 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3437943 | Administered SC |
| DRUG | Dulaglutide | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2021-05-13
- Primary completion
- 2022-07-08
- Completion
- 2022-10-27
- First posted
- 2021-04-30
- Last updated
- 2023-07-03
- Results posted
- 2023-07-03
Locations
43 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04867785. Inclusion in this directory is not an endorsement.